Clinical Trials Prove Med-Tech Systems International's Air Sterilization Device Dramatically Reduces Symptoms of Respiratory Illnesses.

New Product Exhibits Great Potential to Impact Health Care Costs and Quality of Life for Sufferers of COPD and Other Respiratory Diseases

ADDISON, Texas -- A clinical research study on Med-Tech Systems International's Aurora M600 air sterilization device has demonstrated its effectiveness in dramatically reducing symptoms of respiratory illnesses, such as asthma, emphysema, allergies, and Chronic Obstructive Pulmonary Disease (COPD). The study demonstrates the value of the device in decreasing the severity of symptoms, acuity of care as well as the need for doctor and hospital visits and medication use.

After two months of product use, a physician's assessment shows a statistically significant decrease in symptoms of chronic respiratory illnesses by 67 percent compared to a baseline study of symptoms. Additionally, after two months of product use, the patients' self assessment shows an average decrease in asthma, allergy and COPD by 55 percent, compared to the baseline study. During the two-month trials, 70 percent of patients used fewer rescue medications, such as fast-acting inhalers, and 84 percent of patients, even those accustomed to frequent doctor visits, reported that the device helped enough that they hadn't had to see a doctor within the study time. Data from a quality of life questionnaire showed that the mean number of doctor visits went from two to almost zero after a month of product use. And, average peak flow meter (spirometer readings) improved by 28 percent after two months of product use.

The results demonstrate the Aurora M600 could serve as a valuable tool for physicians in treating chronic respiratory illnesses and reducing total health care costs, particularly among the senior population hard hit by these illnesses. COPD is the fourth leading cause of death in the United States and costs more than $32 billion dollars in medical expenses and lost work hours each year. Furthermore it will, according to the American Thoracic Society estimates, cost the U.S. health care system more than $800 billion dollars over the next 20 years. The problem has spurred a Congressional mandate to find adequate treatments for this persistent condition, which is placing a severe strain on Medicare and Medicaid systems.

"The outcomes of these clinical trials give new hope to people suffering from the disabling effects of asthma and other respiratory illnesses," said Dr. John M. Joseph, principal investigator of the study. "The Aurora M600 made a definite impact on the condition of participants in the trials. The ability of this device to reduce the need for costly medication, doctor visits and hospitalizations, paired with its positive impact on patients' quality of life is heartening news for patients suffering from these conditions."

Unlike air filters currently on the market, the Aurora M600 actually sterilizes air, making it possible for patients suffering from respiratory illnesses to breathe easier with better quality air. In fact, 82 percent of patients in the trials experienced fewer symptoms in the mornings after having slept in a room where the device worked all night. Not only did the reduction in symptoms help decrease doctor visits and reliance on medications, several study participants reported being able to enjoy activities they had previously been unable to do, such as travel, outdoor activities and exercise.

"As a COPD sufferer, I get pneumonia three to four times per year. But since I've been using the Aurora M600, I feel much better and have not contracted pneumonia," said Janice Schiftner, a clinical trial participant. "With these improvements in my health and quality of life, the device has sold itself. I'm hopeful that the outcomes of the clinical trials will encourage the Centers for Medicare and Medicaid Services to consider the Aurora M600 as a reimbursable medical device."

Methodology

The controlled study, conducted by Trinity Clinical Research, LLC, involved 56 participants divided into two groups. Forty-six patients were placed in the "active" group, and used the real product for the entire two months. Ten patients were placed in a sub group where they used a placebo product for one month and used the Aurora M600 for one month. Patients with moderate asthma, allergy or COPD were selected to be included in the study. The air sterilization device was set up in the patient's bedroom and allowed to work 24 hours per day. Research clinicians gauged patients' asthma, allergy and COPD conditions through observation, patient assessment, clinical examinations and monitoring using medical equipment, such as spirometers.

"We are pleased with, but certainly not surprised by the outcome of the clinical trials that show the effectiveness of the Aurora M600 in treating respiratory illnesses," said John Potter, president and CEO, Med-Tech Systems International. "We are proud to have developed a unique product that has the potential to change the lives of the millions of Americans suffering from respiratory illnesses and to make a significant positive impact on ever-increasing health care costs for individuals, private insurance companies, and Medicare and Medicaid."

About Med-Tech Systems International

Headquartered in Addison, Texas, Med-Tech Systems International has led the way in developing personal air sterilization devices to help the millions of individuals suffering from allergies and respiratory illnesses, including Chronic Obstructive Pulmonary Disease (COPD), asthma and emphysema. Through its patent-pending, proprietary technology, the company's Aurora M600 is the only personal product on the market proven to actually sterilize air by destroying living organisms, such as bacteria, mold, viruses and mold spores, as well as a full range of hazardous gas molecules and allergens, all of which can dramatically exacerbate the symptoms and severity of respiratory illnesses.

The company was founded in 2001 by entrepreneur John Potter, who discovered that the same technology used by the U.S. Department of Defense and the U.S. Department of Renewable Energy to defend against biological warfare could be used in a consumer application as a medical device. This technology, called photocatalytic oxidation, was developed at Sandia Laboratories more than 25 years ago.